Evidence map›Paper›PMID 41525868›Full record

ArticleJournal of advanced research2026

Rapid profiling of polymyxin B susceptibility in Gram-negative bacteria with a novel polymyxin-derived fluorescent probe.

Bing Zhang, Wanida Phetsang, Sanjaya Kc, Mark S Butler, Ruby Pelingon, Alysha G Elliott, Maite Amado, Alejandra Gallardo-Godoy, Matthew A Cooper, Mark A T Blaskovich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bing ZhangCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Wanida PhetsangCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Sanjaya KcCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Mark S ButlerCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Ruby PelingonCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia(1).
Alysha G ElliottCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia; Biointelect Pty Ltd, Brisbane, Queensland, Australia(1).
Maite AmadoCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Alejandra Gallardo-GodoyCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
Matthew A CooperCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia; Sitala Bio Ltd, Unit D6, Grain House, Cambridge CB22 5LD, UK(1).
Mark A T BlaskovichCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: m.blaskovich@uq.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPolymyxins are considered last-resort antibiotics for treating Gram-negative bacterial infections. The alarming global rise in polymyxin-resistant bacteria coupled with the slowness of conventional antimicrobial susceptibility testing methods leads to an unmet need for rapid susceptibility testing to facilitate timely and targeted therapeutic interventions.

objectivesIn this study, we aimed to develop novel polymyxin-derived fluorescent probes and improve the identification of polymyxin resistance by using these pathway-specific tools.

methodsWe designed, synthesized, and profiled a polymyxin-fluorophore derivative (PMX-NBD) with the small fluorophore NBD attached the central cyclic core of polymyxin via a triazole linker. We then applied PMX-NBD to develop RAPID

resultsIn contrast to many previously reported polymyxin probes, the fluorescent PMX-NBD retains the antimicrobial activity and profile of the parent polymyxin. Furthermore, we tested probe labeling in 49 strains encompassing E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus with a range of polymyxin sensitivity, leading to a susceptibility testing method RAPID

conclusionsThe RAPID

Indexed as

Anti-Bacterial AgentsFluorescent DyesGram-Negative BacteriaPolymyxin BDrug Resistance, BacterialFlow CytometryFluorescent Chemosensor CompoundsHumansMicrobial Sensitivity TestsPolymyxinsAnti-Bacterial AgentsFluorescent Chemosensor CompoundsFluorescent DyesPolymyxin BPolymyxinsAntimicrobial resistanceFlow cytometryFluorescent probePolymyxin B

Identifiers

PMID41525868
PMCPMC13669591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.